PPD Unit AES Acquires Bioclinica Site Business

AES logo

Accelerated Enrollment Solutions, a business unit of Wilmington’s Pharmaceutical Product Development, has purchased the clinical research site business of clinical trial development company Bioclinica.

AES said the acquisition solidifies its global leadership in patient access and site conduct. The company says the expansion means it now services over 180 research sites in 20 countries across five continents. The companies declined to disclose financial terms of the acquisition. 

AES has traditionally served customers from its sites in North America, Europe and South Africa. Adding the site business of Princeton, N.J.-based Bioclinica extends AES’ reach to China, Latin America, and Western Europe. Furthering its impact on the clinical trial supply chain, AES hopes to set a new productivity standard and deliver more patients from fewer sites in less time.

“With these new assets operating on five continents, AES is a place where customers can receive 50 to 100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe,” said Roger Smith, senior vice president and general manager of AES. 

“We can now address two major impediments to meaningful improvement in site selection and patient enrollment – namely, investigator site capacity and the ability to predictably bring new patients into research with our data modeling and analytical capabilities. Our approach can reduce customers’ reliance on patient availability from investigator databases and practices.” 

David Herron, president and CEO of Bioclinica, said, “We believe PPD’s AES business unit is an outstanding strategic fit for the global site business. Both organizations have long been committed to clinical research and together they will provide excellent value for sponsors and CROs. This transaction enables AES to take patient access and site conduct to a new level, while enabling Bioclinica to accelerate its delivery of exceptional services in medical imaging, cardiovascular safety, eClinical and trial software, and drug safety solutions.”

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. It has offices in 48 countries and more than 21,000 employees worldwide.

Lindsey Baron, NCBiotech Writer
Mon, 09/09/2019 - 12:58